Earnings Releases

NI Holdings, Inc. reported financial results for the quarter and year ended December 31, 2025.

“On March 6, 2026, the Company issued a press release announcing its financial results for the quarter and year ended December 31, 2025.”

PMV Pharmaceuticals, Inc. reported the full year ended December 31, 2025 results: net income Net loss for the year ended December 31, 2025, was $77.7 million.

“On March 6, 2026, PMV Pharmaceuticals, Inc. issued a press release announcing its financial results for the year ended December 31, 2025.”

Bluejay Diagnostics, Inc. reported the fiscal year ended December 31, 2025 results: net income net losses of approximately $6.8 million.

“The Company expects to report $5.2 million in cash and cash equivalents and $6.0 million in stockholders’ equity as of December 31, 2025, following successful completion of a $3.8 million warrant-inducement financing in April 2025 and an additional $4.5 million PIPE financing in October 2025. The Company incurred net losses of approximately $6.8 million for the fiscal year ended December 31, 2025.”

Solid Biosciences Inc. reported preliminary financial results for the fourth quarter and fiscal year ended December 31, 2025.

“Although the Company has not finalized its full financial results for the fourth quarter and fiscal year ended December 31, 2025, the Company expects to report cash, cash equivalents and available-for-sale securities of approximately $187.9 million as of December 31, 2025.”

Jade Biosciences, Inc. reported the fourth quarter and full year ended December 31, 2025 results: net income Net loss totaled $31.9 million for the fourth quarter ended December 31, 2025, compared to a net loss of $30.1 million f.

“On March 6, 2026, Jade Biosciences, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the quarter and year ended December 31, 2025.”

MARKETWISE, INC. updated its the fourth quarter ended December 31, 2025 guidance (raised).

“On March 6, 2026, MarketWise, Inc. (the “Company”) issued an earnings press release announcing its financial results for the fourth quarter ended December 31, 2025.”

Greenidge Generation Holdings Inc. reported the fourth quarter and fiscal year ended December 31, 2025 results: revenue Total revenue of $11.5 million, net income Net income of $1.9 to $2.9 million.

“million in potential future earnouts; and • Held 74 Bitcoin valued at $6.5 million as of December 31, 2025. Fourth Quarter 2025 Preliminary Financial Results: • Total revenue of $11.5 million, a reduction of $3.7 million from Q3 2025; • Net income of $1.9 to $2.9 million, a reduction of $10.1 to $9.1 million from Q3 2025; • EBITDA of $4.5 to $5.5 million, a reduction”

GENESCO INC reported the twelve months ended January 31, 2026 results: revenue Net sales of $2.4 billion, EPS GAAP EPS was $1.25 vs. ($1.80) last year and Non-GAAP EPS was $1.45 vs. $0.94 last year.

“Fiscal 2026 Financial Summary • Net sales of $2.4 billion increased 5% compared to FY25 • Comparable sales increased 6%, with stores up 6% and e-commerce up 4% • E-commerce sales represented 25% of retail sales for both this year and last year • Selling and administrative expenses leveraged 120 basis points compared to last year • GAAP EPS was $1.25 vs. ($1.80) last year and Non-GAAP EPS was $1.45 vs. $0.94 last year”

GENESCO INC reported the three and twelve months ended January 31, 2026 results: revenue Net sales of $800 million, EPS GAAP EPS was $4.43 vs. $3.06 last year and Non-GAAP EPS was $3.74 vs. $3.26 last year.

“Genesco Inc. (NYSE: GCO) today reported fourth quarter and full fiscal year results for the three and twelve months ended January 31, 2026. Fourth Quarter Fiscal 2026 Financial Summary • Net sales of $800 million increased 7% compared to Q4FY25 • Comparable sales increased 9%, with stores up 9% and e-commerce up 8% • E-commerce sales represented 31% of retail sales compared to 30% last year • Selling and administrative expenses leveraged 140 basis points compared to last year • GAAP EPS was $4.43 vs. $3.06 last year and Non-GAAP EPS was $3.74 vs. $3.26 last year”

GENESCO INC reported financial results for the fourth fiscal quarter ended January 31, 2026.

“On March 6, 2026, Genesco Inc. issued a press release announcing results of operations for the fourth fiscal quarter ended January 31, 2026.”

AtaiBeckley Inc. reported financial results for fourth quarter and year ended December 31, 2025.

“On March 6, 2026, AtaiBeckley Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2025 and provided a corporate and clinical update.”

HURCO COMPANIES INC reported the first fiscal quarter ended January 31, 2026 results: revenue $42,868,000, net income net loss of $3,468,000, or $0.54 loss per diluted share, EPS $0.54 loss per diluted share.

“loss of $4,320,000, or $0.67 loss per diluted share, for the corresponding period in fiscal year 2025. ​ Sales and service fees for the first quarter of fiscal year 2026 were $42,868,000, a decrease of $3,546,000, or 8%, compared to the corresponding prior year period, and included a favorable currency impact of $1,813,000, or 4%, when translating foreign sales to”

SABINE ROYALTY TRUST reported oil production for December 2025 and the gas production for November 2025 results: EPS $0.286230 per unit.

“Sabine Royalty Trust News Release SABINE ROYALTY TRUST ANNOUNCES MONTHLY CASH DISTRIBUTION FOR MARCH 2026 Dallas, Texas, March 6, 2026 – Argent Trust Company, as Trustee of the Sabine Royalty Trust (NYSE: SBR), today declared a cash distribution to the holders of its units of beneficial interest of $0.286230 per unit, payable on March 30, 2026, to unit holders of record on March 16, 2026.”

Santander Holdings USA, Inc. reported financial results for Fourth Quarter 2025.

“SANTANDER HOLDINGS USA, INC. Fourth Quarter 2025 Fixed Income Investor Presentation”

LEXICON PHARMACEUTICALS, INC. reported the three months and year ended December 31, 2025 results: revenue $5.5 million and $49.8 million for the quarter and year ended December 31, 2025, respectively.

“LEXICON PHARMACEUTICALS REPORTS FOURTH QUARTER 2025 FINANCIAL RESULTS AND PROVIDES CLINICAL UPDATES”

JOHN WILEY & SONS, INC. reported the third quarter ended January 31, 2026 results: revenue $410 million, EPS $0.56. Guidance reaffirmed.

“discovery, innovation, and learning, today reported results for the third quarter ended January 31, 2026. THIRD QUARTER SUMMARY • GAAP performance vs. prior year : Revenue of $410 million up 1%; Operating Income of $63 million up 21%; and Diluted Earnings Per Share (EPS) of $0.56 compared to prior year loss of ($0.43) • Adjusted Results at constant currency :”

SMITH & WESSON BRANDS, INC. reported the third quarter of fiscal 2026, ended January 31, 2026 results: revenue $135.7 million, net income $3.8 million, EPS $0.08 per diluted share. Guidance raised.

“Smith & Wesson Brands, Inc. Reports Third Quarter Fiscal 2026 Financial Results - Q3 Net Sales of $135.7 Million - Q3 Gross Margin of 26.2%; Non-GAAP Gross Margin of 26.1% - Q3 EPS of $0.08/Share; Q3 Adjusted EPS of $0.08/Share MARYVILLE, Tenn., March 5, 2026 – Smith & Wesson Brands, Inc. (NASDAQ Global Select: SWBI) , a U.S.-based leader in firearm manufacturing and design, today announced financial results for the third quarter of fiscal 2026, ended January 31, 2026. Financial Highlights • Net sales were $135.7 million, an increase of $19.8 million, or 17.1%, from the comparable quarter last year. • Gross margin was 26.2% compared with 24.1% in the comparable quarter last year. • Net income was $3.8 million, or $0.08 per diluted share, compared with $2.1 million, or $0.05 per diluted share, for the comparable quarter last year. • Non-GAAP net income was $3.6 million, or $0.08 per diluted share, compared with $1.4 million, or $0.03 per diluted share, for the comparable quarter last ye”

ENTRAVISION COMMUNICATIONS CORP reported financial results for the three- and twelve-month periods ended December 31, 2025.

“On March 5, 2026, Entravision Communications Corporation (the “Company”) issued a press release announcing its results of operations for the three- and twelve-month periods ended December 31, 2025.”

Altimmune, Inc. reported financial results for the fourth quarter and full year ended December 31, 2025.

“On March 5, 2026, Altimmune, Inc. (the “Company”) issued a press release announcing the Company’s financial results for its fourth quarter and full year ended December 31, 2025.”

aTYR PHARMA INC reported financial results for the year ended December 31, 2025.

“On March 5, 2026, aTyr Pharma, Inc. issued a press release announcing financial results for the year ended December 31, 2025.”

SANDRIDGE ENERGY INC reported the quarter and year ended December 31, 2025 results: net income $21.6 million, or $0.59 per basic share during the fourth quarter of 2025, EPS $0.59 per basic share.

“SandRidge Energy, Inc. issued a press release announcing financial and operational results for the quarter and year ended December 31, 2025.”

AUDIOEYE INC reported Q1 2026 and FY 2026 results: revenue between $10.5M and $10.6M (Q1 2026), between $43M and $44.5M (FY 2026), EPS between $0.17 and $0.18 per share (Q1 2026 adjusted EPS), at least 30% growth (FY 2026 adjusted EPS). Guidance raised.

“AudioEye expects revenue of between $10.5M and $10.6M for the first quarter of 2026 and between $43M and $44.5M for the full year 2026. The Company expects adjusted EBITDA of between $2.2M and $2.3M for the first quarter of 2026, with at least 30% adjusted EBITDA growth for full year 2026. The Company expects adjusted EPS of between $0.17 and $0.18 per share for the first quarter of 2026 and at least 30% growth for the full year 2026.”

AUDIOEYE INC reported FY 2025 results: EPS $0.72 per share (adjusted EPS).

“Total revenue increased 15% to a record $40.3M in 2025 from $35.2M in 2024.”

AUDIOEYE INC reported Q4 2025 results: EPS $0.22 per share (adjusted EPS).

“Total revenue increased 8% to a record $10.5M from $9.7M in the same prior year period.”

AUDIOEYE INC reported fiscal quarter and fiscal year ended December 31, 2025 results: revenue $10.5M (Q4 2025), $40.3M (FY 2025), net income net loss was $1.1M (Q4 2025), net loss was $3.1M (FY 2025), EPS $(0.08) per share (Q4 2025), $(0.25) per share (FY 2025).

“AudioEye, Inc. (Nasdaq: AEYE) (“AudioEye” or the “Company”) , the industry-leading digital accessibility company, reported financial results for the fourth quarter and full year ended December 31, 2025.”

Information Services Group Inc. reported the fourth quarter and full year ended December 31, 2025 results: revenue $61.2 million, net income $2.6 million, EPS $0.05.

“+203 517 3104 michael.sherrick@isg-one.com ​ ​ ​ Information Services Group Announces Fourth-Quarter and Full-Year 2025 Results ​ ● Reports fourth-quarter GAAP revenues of $61.2 million, at the top end of guidance and up 6% versus prior year ● Reports fourth-quarter GAAP net income of $2.6 million, GAAP EPS of $0.05 and adjusted EPS of $0.08; Prior year GAAP”

CarParts.com, Inc. reported fourth quarter and fiscal year ended January 3, 2026 results: revenue Net sales decreased to $120.4 million for the fourth quarter; Net sales decreased 7% to $547.5 million for the fiscal ye, net income Net loss was ($11.6) million for the fourth quarter; Net loss was ($50.4) million for the fiscal year, EPS ($0.17) per share for the fourth quarter; ($0.82) per share for the fiscal year.

“2025 (53 weeks) Summary vs. Fiscal Year 2024 (52 weeks) ● Closed $35.7 million strategic investment from A-Premium, ZongTeng Group, and CDH Investments. ● Net sales decreased 7% to $547.5 million. ● Gross profit of $179.3 million vs. $196.7 million, with gross margin of 32.8%. ● Net loss was ($50.4) million, or ($0.82) per share, compared to a net loss”

RING ENERGY, INC. reported the fourth quarter and year ended December 31, 2025 results: revenue $66.9, net income net loss of $12.8 million, or $(0.06) per diluted share, EPS $(0.06) per diluted share. Guidance reaffirmed.

“- All Products ($/Boe) $35.45 $41.10 (14)% $46.14 (23)% $41.55 $50.94 (18)% Realized Price - Crude Oil ($/Bo) $57.47 $64.32 (11)% $68.98 (17)% $63.53 $74.87 (15)% Revenues ($MM) $66.9 $78.6 (15)% $83.4 (20)% $307.2 $366.3 (16)% Net Income (Loss) ($MM) $(12.8) $(51.6) 75% $5.7 (325)% $(34.7) $67.5 (151)% Adjusted Net Income 1 ($MM) $3.6 $13.1 (73)% $12.3 (71)%”

Gevo, Inc. reported the full year ended December 31, 2025 results: revenue $161 million. Guidance reaffirmed.

“Revenue of $45 million in the fourth quarter, and $161 million in the full year 2025.”

Gevo, Inc. reported the fourth quarter ended December 31, 2025 results: revenue $45 million. Guidance reaffirmed.

“o Revenue of $45 million in the fourth quarter, and $161 million in the full year 2025. o Loss from operations of $2.2 million for the fourth quarter.”

CorMedix Inc. updated its the fourth quarter and full year ended December 31, 2025 guidance (reaffirmed).

“On March 5, 2026, CorMedix Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter and full year ended December 31, 2025.”

Kura Oncology, Inc. reported the fourth quarter ended December 31, 2025 results: revenue Net product revenue: $2.1 million; Collaboration revenue: $15.2 million.

“Fourth Quarter 2025 Financial Results • Net product revenue: $2.1 million (first five weeks of commercial sales following November 13 approval of KOMZIFTI). • Collaboration revenue: $15.2 million, compared to $53.9 million for Q4”

Quanex Building Products CORP reported fiscal 2026 results: revenue $1.84 billion to $1.87 billion. Guidance initiated.

“we estimate we will generate net sales of $1.84 billion to $1.87 billion, which we expect will yield approximately $240 million to $245 million in Adjusted EBITDA* in fiscal 2026.”

Quanex Building Products CORP reported three months ended January 31, 2026 results: revenue $409.1 million, net income ($4.1), EPS ($0.09).

“Looking ahead, we continue to be optimistic about our prospects for profitable growth and value creation.” First Quarter 2026 Results Summary Quanex reported net sales of $409.1 million during the three months ended January 1, 2026, which represents an increase of 2.3% compared to $400.0 million for the same period in 2025, mainly due to foreign exchange”

OptimizeRx Corp reported fiscal year 2026 results: revenue $109 million and $114 million. Guidance initiated.

“The Company is also updating its fiscal year 2026 guidance at this time and is expecting revenue to be between $109 million and $114 million with Adjusted EBITDA to be between $21 million and $25 million.”

OptimizeRx Corp reported fourth quarter and full year ended December 31, 2025 results: revenue Q4 revenue of $32.2 million; Full year revenue for 2025 came in at $109.4 million, net income Q4 net income ... $5.0 million; GAAP net income for the full year of 2025 totaled $5.1 million, EPS $0.26 per diluted share (Q4); $0.27 per diluted share (full year 2025). Guidance initiated.

“On March 5, 2026 , the Company issued a press release announcing its financial results for the fourth quarter and full year ended December 31, 2025, providing key performance indicators, updated 2026 guidance and announcing a new $10 million share repurchase program.”

Teads Holding Co. reported Twelve Months Ended December 31, 2025 results: revenue $1,300.5 million, net income Net loss of $517.1 million.

“and $17.6 million (unchanged at €15.0 million) outstanding under a short-term overdraft facility assumed in the Acquisition. Full Year 2025 Financial Results: • Revenue of $1,300.5 million, an increase of $410.6 million, or 46%, compared to $889.9 million in the prior year period primarily due to the Acquisition. Results include net favorable foreign currency”

Teads Holding Co. reported Three Months Ended December 31, 2025 results: revenue $352.2 million, net income Net loss of $428.2 million.

“10%, representing anticipated annualized cost savings of approximately $35 million to $40 million when fully implemented. Fourth Quarter 2025 Financial Highlights: • Revenue of $352.2 million, an increase of $117.6 million, or 50%, compared to $234.6 million in the prior year period, primarily due to the acquisition (the “Acquisition”) by Outbrain Inc. (“Outbrain”) of”

Silence Therapeutics plc reported the fourth quarter and full year ended December 31, 2025 results: revenue $0.6 million, net income $88.6 million, EPS $0.63 basic and diluted net loss per share.

“Full Year 2025 Financial Results • Cash Position: Cash, cash equivalents, and short-term investments were $85.1 million as of December 31, 2025. This includes cash and cash equivalents of $11.3 million and short-term investments of $73.8 million. • Collaboration Revenue: Collaboration revenue was $0.6 million for the year ended December 31, 2025, compared to $43.3 million for the year ended December 31, 2024. The decrease for 2025 was primarily due to revenue associated with the Hansoh collaboration that concluded in 2024 and a $17.4 million decrease in revenue related to the AstraZeneca collaboration. • R&D Expenses: Research and development (R&D) expenses were $67.8 million for the year ended December 31, 2025, compared to $67.9 million for the year ended December 31, 2024. • G&A Expenses: General and administrative (G&A) expenses were $22.3 million for the year ended December 31, 2025, compared to $26.9 million for the year ended December 31, 2024. The decrease for 2025 was primaril”

Nutex Health Inc. reported fourth quarter and year ending December 31, 2025 results: revenue $151.7 million, net income $11.8 million, EPS $10.48.

“of $185.6 million, and long-term debt, net of $29.2 million. 1 Financial highlights for the three months ended December 31, 2025 : • Total revenue decreased $105.9 million to $151.7 million for the three months ended December 31, 2025 as compared to total revenue of $257.6 million for the same period in 2024, a decrease of 41.1%. • The Company attributes the $105.9”

Nutex Health Inc. reported full year 2025 results: revenue $875.3 million, net income $70.8 million, EPS $10.48.

“on Form 8-K. --- EX-99.1 (EX-99.1) --- NUTEX HEALTH REPORTS 2025 FINANCIAL RESULTS AND ANNOUNCES SECOND STOCK REPURCHASE PROGRAM FULL YEAR 2025 HIGHLIGHTS: • Total revenue of $875.3 million for the year 2025 versus $479.9 million for the year 2024, an increase of 82.4% • Net income attributable to Nutex Health of $70.8 million for 2025 versus net income of $52.1”

Ambiq Micro, Inc. reported fourth quarter and full year ended December 31, 2025 results: revenue Full Year 2025 net sales of $72.5 million, net income Net loss attributable to common stockholders $(10,679), EPS Net loss per share attributable to common stockholders $(0.58). Guidance reaffirmed.

“On March 5, 2026, Ambiq Micro, Inc. (the "Company") issued a press release to report financial results for its fourth quarter and full year ended December 31, 2025.”

GoPro, Inc. reported fourth quarter and year ended December 31, 2025 results: revenue $106 million.

“Revenue was $202 million, flat year-over-year.”

MONROE CAPITAL Corp reported financial results for the fourth quarter and full year ended December 31, 2025.

“On March 5, 2026, Monroe Capital Corporation (the “Company”) issued a press release announcing the Company’s financial results for the fourth quarter and full year ended December 31, 2025.”

Wheeler Real Estate Investment Trust, Inc. reported financial results for three and twelve months ended December 31, 2025.

“On March 5, 2026, Wheeler Real Estate Investment Trust, Inc. (the “Company”), issued a press release announcing that it had reported its financial and operating results for the three and twelve months ended December 31, 2025.”

Guidewire Software, Inc. reported the fiscal quarter ended January 31, 2026 results: revenue $359.1 million, net income $60.1 million, EPS $0.70. Guidance raised.

“Total revenue for the second quarter of fiscal year 2026 was $359.1 million, an increase of 24% from the same quarter in fiscal year 2025.”

BJ's Wholesale Club Holdings, Inc. reported financial results for fourth quarter (thirteen weeks) and four quarters (fifty-two weeks) of fiscal year 2025 ended January 31, 2026.

“On March 5, 2026 , BJ’s Wholesale Club Holdings, Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter (thirteen weeks) and four quarters (fifty-two weeks) of fiscal year 2025 ended January 31, 2026.”

Burlington Stores, Inc. reported the fiscal year ended January 31, 2026 results: net income $610 million, EPS $9.51 per share. Guidance initiated.

“o FY25 total sales grew 9%, and comparable store sales increased 2% o FY25 net income was $610 million, and diluted EPS was $9.51”

Burlington Stores, Inc. reported the fourth quarter ended January 31, 2026 results: revenue $3,643 million, net income $310 million, EPS $4.84 per share. Guidance initiated.

“positioned the business to aggressively chase sales.” Fiscal 2025 Fourth Quarter Operating Results • Total sales increased 11% compared to the fourth quarter of Fiscal 2024 to $3,643 million, while comparable store sales increased 4% compared to the fourth quarter of Fiscal 2024. • Gross margin rate as a percentage of net sales was 43.7% vs. 42.9% for the fourth”

REGENXBIO Inc. reported financial results for the fourth quarter and year ended December 31, 2025.

“REGENXBIO Inc. (the “Company”) issued a press release regarding its results of operations and financial condition for the quarter and year ended December 31, 2025.”